“Testosterone treatment in men with hypogonadism…..trials with a sufficiently large sample and a sufficiently long duration to determine the effect of testosterone on the incidence of fractures are needed.”

“In a subtrial of a double-blind, randomized, placebo-controlled trial that assessed the cardiovascular safety of testosterone treatment in middle-aged and older men with hypogonadism, we examined the risk of clinical fracture in a time-to-event analysis. Eligible men were 45 to 80 years of age with preexisting, or high risk of, cardiovascular disease; one or more symptoms of hypogonadism; and two morning testosterone concentrations of less than 300 ng per deciliter…..”

“The full-analysis population included 5204 participants (2601 in the testosterone group and 2603 in the placebo group).”

“After a median follow-up of 3.19 years, a clinical fracture had occurred in 91 participants (3.50%) in the testosterone group and 64 participants (2.46%) in the placebo group….”

“Among middle-aged and older men with hypogonadism, testosterone treatment did not result in a lower incidence of clinical fracture than placebo. The fracture incidence was numerically higher among men who received testosterone…..”

–

P.J.Snyder, et al

Testosterone Treatment and Fractures in Men with Hypogonadism

New England Journal Of Medicine — Volume 390 #3 — January 18, 2024 — page 203

–

–

TheETG free pdf packets……..

—– ETG info: drugs & drug testing, sham & scam

Across the last 17 years downloads of TheETG free pdf packets have averaged over 4500 per year, and ranged between 2000 – 11,000.